Mylan To File CNS NDAs/ANDAs By Year End Via Synthon Deal
Executive Summary
Mylan will file several NDAs and ANDAs for central nervous system treatments over the next two months as part of its collaboration with the Dutch pharmaceutical firm Synthon.